Ironwood Pharmaceuticals Inc represents a strong dedication to improving the lives of patients through innovative medicines. Their corporate philosophy is centered around delivering breakthrough treatments and therapies that address unmet medical needs. With a focus on gastrointestinal diseases such as irritable bowel syndrome with constipation (IBS-C) and gastrointestinal (GI) disorders, Ironwood Pharmaceuticals aims to provide effective solutions for patients worldwide. Their commitment to scientific excellence, collaboration, and patient advocacy drives their pursuit of transformative healthcare solutions. Ironwood Pharmaceuticals Inc is committed to making a positive impact within the pharmaceutical industry by advancing patient care and wellbeing.

Ironwood Pharmaceuticals Inc is primarily present in the United States.

Ironwood Pharmaceuticals Inc has achieved significant milestones since its inception. Notably, the company successfully developed and gained regulatory approval for its flagship drug, LINZESS® (linaclotide), which is used to treat irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC). Ironwood Pharmaceuticals Inc also formed a strategic collaboration with Allergan plc (now part of AbbVie Inc) to co-develop and co-commercialize LINZESS®. Moreover, the company advanced its pipeline with the development of potential treatments for various gastrointestinal and renal disorders. Ironwood Pharmaceuticals Inc's commitment to innovation and its focus on improving patients' lives solidify its position as a leading pharmaceutical company in the market.

Ironwood Pharmaceuticals Inc is a leading biotechnology company specializing in the development and commercialization of innovative medicines. Founded in 1998, Ironwood has since focused on advancing treatments for gastrointestinal diseases and fibrotic conditions. With a strong dedication to research and development, the company has successfully brought several approved drugs to market. Ironwood Pharmaceuticals Inc has established itself as a key player in the pharmaceutical industry, continuously striving to improve patients' lives. Through its commitment to scientific excellence and breakthrough therapies, Ironwood Pharmaceuticals Inc has positioned itself as a trusted name in the healthcare sector.

The main competitors of Ironwood Pharmaceuticals Inc in the market include Allergan plc, AstraZeneca plc, Pfizer Inc, and Takeda Pharmaceutical Company Limited.

Ironwood Pharmaceuticals Inc is primarily active in the biotechnology and pharmaceutical industries.

The business model of Ironwood Pharmaceuticals Inc revolves around developing and commercializing innovative medicines for patients with gastrointestinal (GI) diseases. The company focuses on discovering, developing, and marketing medicines for indications like irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC). Ironwood Pharmaceuticals Inc leverages its expertise in the GI field to identify and advance potential therapies that address significant unmet needs in patient care. By prioritizing research and development, the company aims to improve the lives of individuals suffering from GI disorders and enhance their overall quality of life.

مُعامل القيمة السوقية إلى الأرباح لـ Ironwood Pharmaceuticals هو ١٧٫٢٩.

مُعامِل القيمة إلى المبيعات Ironwood Pharmaceuticals هو ١٫٨٦.

نقاط جودة AlleAktien لـ Ironwood Pharmaceuticals هي 4/10.

المتوقعة Ironwood Pharmaceuticals الإيرادات هي ٣٦٣٫٤٧ مليون. USD.

صافي الربح المتوقعة Ironwood Pharmaceuticals هو ٣٩٫١٠ مليون. USD.

Ironwood Pharmaceuticals Inc is a biopharmaceutical company based in Cambridge, Massachusetts, that focuses on the research, development, and commercialization of innovative drugs for the treatment of serious diseases. The business model of Ironwood is based on the invention and commercialization of new drugs to improve the health and quality of life of patients. The company specializes in the development of therapeutics in the fields of gastroenterology, hepatology, oncology, and neuroscience. An important segment of Ironwood's business model is partnerships with other companies. Ironwood collaborates with numerous partners and hospitals to optimize the research and development of therapeutics. For example, Ironwood works with the Canadian company Allergan to market the gastrointestinal motility agent Linzess. Ironwood also has its own sales and marketing organization that focuses on promoting and marketing its products. The company aims to bring its products to the global market and maintain its leading position in the industry. One of Ironwood's leading products is Linzess, the first and only prescription medication for the treatment of chronic constipation and irritable bowel syndrome with constipation (IBS-C) in adults. Linzess aims to alleviate the symptoms of these conditions by increasing intestinal motility and facilitating bowel movements. Another important product of Ironwood is Zurampic, a medication for the treatment of gout in adults in combination with a xanthine oxidase inhibitor. Zurampic helps reduce uric acid in the body by increasing its excretion through the kidneys. Ironwood also has products in the pipeline that are in different stages of clinical development. These include IW-3718 for the treatment of reflux diseases and Olinciguat for the treatment of cystic fibrosis-associated respiratory complications. Overall, Ironwood has successfully built a business model specializing in the discovery and development of new drugs, with a focus on gastroenterology, hepatology, oncology, and neuroscience. The company works closely with partners and hospitals to optimize the research and development of therapeutics and market its products worldwide. With leading products like Linzess and Zurampic, along with promising products in the pipeline, Ironwood remains an important player in the industry.

يوزع Ironwood Pharmaceuticals أرباحًا قدرها 0 USD من خلال عمليات توزيع موزعة على مدار السنة.

لا يمكن حساب الأرباح السنوية لـ Ironwood Pharmaceuticals في الوقت الحالي أو أن الشركة لا توزع أرباحًا.

الرمز الدولي للأوراق المالية الخاص بـIronwood Pharmaceuticals هو US46333X1081.

رمز WKN لـ Ironwood Pharmaceuticals هو A0X789.

الرمز المُختصر لـ Ironwood Pharmaceuticals هو IRWD.

خلال آخر 12 شهراً، دفعت Ironwood Pharmaceuticals توزيعات أرباح بقيمة . وهذا يعادل عائد توزيعات أرباح يقارب . ومن المتوقع أن تدفع Ironwood Pharmaceuticals خلال الـ12 شهراً القادمة توزيعات أرباح تقدر بـ0 USD.

نسبة توزيعات الأرباح الحالية لـ Ironwood Pharmaceuticals هي .

Ironwood Pharmaceuticals يدفع توزيعات أرباح ربع سنوية. يتم توزيعها في الأشهر .

Ironwood Pharmaceuticals دفعت توزيعات الأرباح كل عام خلال الـ0 سنوات الماضية.

يُتوقع خلال الـ12 شهرًا القادمة توزيع أرباح بقيمة 0 USD. وهذا يعادل عائد توزيعات أرباح قدره 0 %.

Ironwood Pharmaceuticals يُصنف ضمن قطاع 'الصحة'.

لكي تستلم آخر توزيعات أرباح بقيمة 0 USD من Ironwood Pharmaceuticals المُعلن عنها في ١٣‏/٩‏/٢٠٢٤، كان يجب أن تمتلك السهم في محفظتك قبل تاريخ الاستحقاق السابق في ١٣‏/٩‏/٢٠٢٤.

تم توزيع آخر دفعة من الأرباح بتاريخ ١٣‏/٩‏/٢٠٢٤.

في العام 2023، وزعت Ironwood Pharmaceuticals 0 USD كأرباح أسهم.

يتم توزيع أرباح Ironwood Pharmaceuticals بالعملة USD.